A 2025 52-week randomized trial in adults with heterozygous familial hypercholesterolemia (HeFH) found that daily oral Enlicitide 20 mg reduced low-density lipoprotein (LDL) cholesterol by an average of 58% at 24 weeks and maintained about a 55% reduction at 52 weeks versus placebo.
November 21, 2025
high
temporal
Global randomized clinical trial of Enlicitide in adults with genetically elevated LDL cholesterol already on lipid-lowering therapy.